Basic research for the clinical application of drugs for a life style disease to treat Alzheimer's disease.

2017 Fiscal Year Final Research Report

• Project/Area Number: 26293168
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: General internal medicine(including psychosomatic medicine)
• Research Institution: Osaka University
• Principal Investigator: Yamamoto Koichi 大阪大学, 医学系研究科, 講師 (00528424)
• Co-Investigator(Kenkyū-buntansha): 樂木 宏実 大阪大学, 医学系研究科, 教授 (20252679) ; 沢村 達也 信州大学, 学術研究院医学系, 教授 (30243033) ; 里 直行 国立研究開発法人国立長寿医療研究センター, その他部局等, 部長 (70372612)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: アルツハイマー病 / アンジオテンシンII受容体 / AGE受容体 / 降圧薬

Outline of Final Research Achievements

Previous observational studies have implied that angiotensin II type 1 receptor (AT1) blocker (ARB) is superior to the other types of antihypertensives in attenuating the progression of Alzheimer’s disease (AD). The receptor of AGE (RAGE) is shown to be involved in the pathogenesis of AD by binding to amyloid β (Aβ). In this study, we planned to clarify the hypotheses that Aβ activates AT1 via an interaction between AT1 and RAGE on cellular membrane, and that ARB prevents the progression of AD by inhibiting the interaction. In vitro analysis revealed that the binding of Aβ to RAGE activates cellular signaling and undergoes endocytosis by activating AT1, and that ARBs partially inhibited the phenomenon. Further investigation will be required to investigate whether this phenomenon contributes to the progression of AD using mice models.

Free Research Field

老年医学